[EN] POLYCYCLIC DIAZODIOXIDE-BASED BCL-2 PROTEIN ANTAGONIST<br/>[FR] ANTAGONISTE DE PROTEINE BCL-2 A BASE DE DIAZODIOXYDE POLYCYCLIQUE
申请人:RICERCA BIOSCIENCES LLC
公开号:WO2004099162A1
公开(公告)日:2004-11-18
Compounds of Formula 8 are provided: A and B are each independently selected from the group consisting of -NO-, -SO-, and - NR9-. C is a single bond or a double bond. D is selected from the group consisting of single bond, E is selected from the group consisting of single bond, double bond, -NR9-, -0-, -S-, -SO- and -S02-; and m and n are each independently an integer from 0 to 6. R1 to R9 are appropriately selected to optimize physicochemical and/or biological properties such as lipophilicity, bioavailability, pharmacokinetics, Bcl-2 and Bcl-XL activities, metabolism, and the like. R1 and R2, R2 and R3, R3 and R4, R5 and R6, R6 and R7, or R7 and R8 may optionally be joined together to form an aromatic or heteroaromatic ring, including, but not limited to, naphthyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl and the like. The compounds are useful for tumor therapeutic applications. These compounds induce apoptosis in tumor cells mediated through Bcl-2 family of proteins.
提供化学式为8的化合物:A和B分别独立地选自于-NO-,-SO-和-NR9-的群组。C是单键或双键。D选自单键的群组,E选自单键,双键,-NR9-,-0-,-S-,-SO-和-S02-的群组;m和n各自独立地是从0到6的整数。R1到R9适当选择以优化理化和/或生物性质,如亲脂性,生物利用度,药代动力学,Bcl-2和Bcl-XL活性,代谢等。R1和R2,R2和R3,R3和R4,R5和R6,R6和R7或R7和R8可以选择性地结合在一起形成芳香或杂环,包括但不限于萘基,喹啉基,异喹啉基,苯并咪唑基,苯并噁唑基,苯并噻唑基等。这些化合物可用于肿瘤治疗应用。这些化合物通过Bcl-2家族蛋白介导诱导肿瘤细胞凋亡。